CardiaCast: New Hope in HF: The Evolving Evidence for SGLT2 Inhibitors

In this episode, Alanna Morris, MD, MSc, FACC; Javed Butler, MBBS, FACC; John McMurray, MD, FACC; and Muthiah Vaduganathan, MD, FACC, discuss the role of sodium-glucose transport protein 2 inhibitors in the new hope in heart failure (HF). Visit the Clinical Spotlight Series: Shining a Light on New HF Pharmacotherapies online course page for more information and resources. Educational Support provided by AstraZeneca, Cytokinetics, Merck Sharp & Dohme Corp., and Novartis Pharmaceuticals Corporation.